Data from Healint’s Migraine Buddy Platform of One Million Users to Be Presented at European Academy of Neurology Conference June 2018

New Alexa Feature Adds Convenience, Especially for Eighty Percent of
Migraine Patients Who Experience Light Sensitivity During an Attack

SINGAPORE–(BUSINESS WIRE)–#EAN2018Healint,
the developer of Migraine Buddy, the world’s largest migraine tracking
and research platform, today announced data on the impact of migraine on
work productivity, unveiled in a poster
presentation at the Fourth Congress of the European Academy of Neurology
(EAN) June 16-19, 2018.

With its comprehensive network of one million users and 100 million
migraine days tracked on the platform, Migraine Buddy contains
patient reported data that generates real world evidence of the global
burden of migraine worldwide. The study, entitled Evaluating the
Impact of Migraine on Work Productivity in Switzerland Using
Self-Reported Data from the Migraine Buddy Application,
collected
data from 1500 Migraine Buddy users in Switzerland during a 28-day
observation period.

Insights uncovered from the study, co-authored by Healint’s president
and chief executive officer Francois Cadiou, found:

  • The majority – 86.40% – of individuals reported their daily activities
    being affected by migraine.
  • On average, individuals reported missing 31.91 work days per year due
    to migraine.
  • About 2 out of 5 migraine patients (40.13%, n=1500) reported suffering
    from anxiety and/or depression in at least one migraine attack.
  • Migraine is reported to have a considerable impact on the lives of
    individuals.

“This is just a sample of the kinds of real world data we can generate
from our platform to uncover just how impactful this silent disease can
be on the lives of those who suffer,” says Cadiou. “Healthcare and lost
productivity figures associated with migraine are costing the U.S. alone
upwards of $35 billion annually, not to mention the burden the condition
has on the patients themselves. Translating the impact into cost is
necessary in order to help migraineurs finally have a voice. Innovative
technology, as implemented in Migraine Buddy, can finally help patients
and their doctors understand, diagnose and treat this complex condition
for the best possible outcomes.”

Using sensor technologies, deep analytics and machine learning, the
Migraine Buddy platform allows users to easily track all aspects of a
migraine attack, including triggers, symptoms, medications, and pain
intensity.

The Migraine Buddy platform, accessed via iOS and Android mobile devices
and tablets, also includes pure voice control via Amazon’s Alexa, the
first migraine tracking Skill launched in June 2018. The voice-enabled
Skill feature supports the 80 percent of migraineurs who report being
light sensitive during their migraine attacks, according to Migraine
Buddy data. If a user feels an attack coming on, they can use the Alexa
Migraine Buddy skill to log the precise moment their migraine starts and
ends without having to look at the light from their mobile device.

The patient reported data logged in real time generates a migraine
history report that they can easily share with their doctor. Using this
report, patients can better understand their condition; doctors can
accurately diagnose the condition and advise patients on the best course
of treatment.

Healint’s analytics also expedites therapy innovation while reaching the
right patients for efficient clinical trials. Now, with the use of
Healint’s real time views and insights, researchers can successfully
execute high-quality and cost-effective clinical trials with nimble
recruitment, minimal drop-out, and reliable reporting.

“We at Healint are the link between patients, physicians, pharmaceutical
companies and researchers providing the real-time, patient-reported
insights that are necessary to treat this common and debilitating
condition. Ultimately, we aim to provide an artificial-intelligence
powered navigation system that enables each patient to obtain the best
possible treatment at any point in time,” notes Cadiou.

For more information, visit: https://www.healint.com/

Source: https://www.healint.com/services/#researchers
Nicolas
Paris , Deniz Simsek , Deepak Chandrasekhar , Yingdan You , Christopher
Ferruzzi , Francois Cadiou , Healint Pte. Ltd , Singapore , Novartis
Pharma Schweiz AG , Switzerland

This study was funded by
Novartis Pharma Schweiz AG, Switzerland.

*Poster presented
at 4th European Academy of Neurology Congress, Lisbon, Portugal, 16–19
June 2018.*

About Healint:

Healint helps the one billion people who suffer from migraine and other
neurological conditions and is the developer of the world’s largest
migraine tracking and research platform Migraine Buddy©. With more than
one million registered users and 100 million migraine days tracked on
the platform, Migraine Buddy© is the most popular condition-specific app
in the world, and a Top 10 medical app in the USA and Europe. Using deep
analytics and machine learning, Healint generates real-world evidence
for patients, physicians, and researchers to improve treatment outcomes
and expedite clinical trials. Healint collaborates with the world’s
leading scientists to improve the diagnosis, treatment, and lives of
patients suffering from multiple neurological conditions. For more
information, visit:
https://www.healint.com/

Contacts

Scott Public Relations
North America
Lacey Trejo, +1
818-517-7143
Lacey@scottpublicrelations.com
or
Healint
Rest
of the World
Susanna Hasenoehrl, +65 8620 1616
susanna@healint.com